Author Affiliation: Department of Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts.
Coronary artery calcium (CAC) score and high-sensitivity C-reactive protein level are currently the leading contenders to join traditional risk factors in routine clinical assessment of coronary heart disease risk. I do not believe that there is sufficient data to use either at present, and I read with interest the thoughtful critique of CAC scanning by Ridker.1 No conflicts of interest are reported, but Ridker is a co-inventor on patents held by Brigham and Women's Hospital that use high-sensitivity C-reactive protein in assessing cardiovascular disease risk. Having a financial stake in a competitor of CAC scanning for coronary artery disease risk stratification is an important conflict of interest to share with readers.
Cohen PA. Coronary Artery Calcium Scanning and Conflicts of Interest. Arch Intern Med. 2012;172(8):670–670. doi:10.1001/archinternmed.2012.276
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: